Literature DB >> 19517424

Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.

Jelena Klawitter1, Yan Ling Zhang, Jost Klawitter, Nora Anderson, Natalie J Serkova, Uwe Christians.   

Abstract

We developed and validated a semi-automated LC/LC-MS/MS assay for the quantification of imatinib in human whole blood and leukemia cells. After protein precipitation, samples were injected into the HPLC system and trapped onto the enrichment column (flow 5 mL/min); extracts were back-flushed onto the analytical column. Ion transitions [M + H](+) of imatinib (m/z = 494.3 --> 394.3) and its internal standard trazodone (372.5 --> 176.3) were monitored. The range of reliable response was 0.03-75 ng/mL. The inter-day precisions were: 8.4% (0.03 ng/mL), 7.2% (0.1 ng/mL), 6.5% (1 ng/mL), 8.2% (10 ng/mL) and 4.3% (75 ng/mL) with no interference from ion suppression. Autosampler stability was 24 hs and samples were stable over three freeze-thaw cycles. This semi-automated method is simple with only one manual step, uses a commercially available internal standard, and has proven to be robust in larger studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19517424      PMCID: PMC3044679          DOI: 10.1002/bmc.1247

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  24 in total

Review 1.  Imatinib mesylate--a new oral targeted therapy.

Authors:  David G Savage; Karen H Antman
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

2.  Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries.

Authors:  Claudia Müller; Patrick Schäfer; Mylène Störtzel; Susanne Vogt; Wolfgang Weinmann
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-06-15       Impact factor: 3.205

3.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Authors:  E Buchdunger; C L Cioffi; N Law; D Stover; S Ohno-Jones; B J Druker; N B Lydon
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

4.  High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.

Authors:  R Bakhtiar; J Lohne; L Ramos; L Khemani; M Hayes; F Tse
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-03-05       Impact factor: 3.205

5.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

6.  Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.

Authors:  Gunther Guetens; Gert De Boeck; Martin Highley; Herlinde Dumez; Allan T Van Oosterom; Ernst A de Bruijn
Journal:  J Chromatogr A       Date:  2003-12-05       Impact factor: 4.759

7.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Authors:  Catherine Roche-Lestienne; Valerie Soenen-Cornu; Nathalie Grardel-Duflos; Jean-Luc Laï; Nathalie Philippe; Thierry Facon; Pierre Fenaux; Claude Preudhomme
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  Imatinib resistance in multidrug-resistant K562 human leukemic cells.

Authors:  Yanina Assef; Fernanda Rubio; Georgina Coló; Silvana del Mónaco; Mónica A Costas; Basilio A Kotsias
Journal:  Leuk Res       Date:  2008-11-01       Impact factor: 3.156

9.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Authors:  A Hochhaus; S Kreil; A S Corbin; P La Rosée; M C Müller; T Lahaye; B Hanfstein; C Schoch; N C P Cross; U Berger; H Gschaidmeier; B J Druker; R Hehlmann
Journal:  Leukemia       Date:  2002-11       Impact factor: 11.528

10.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Authors:  Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary Gallick; Hui Lin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113

View more
  3 in total

1.  Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism.

Authors:  Jelena Klawitter; Jost Klawitter; Volker Schmitz; Nina Brunner; Amanda Crunk; Kyler Corby; Jamie Bendrick-Peart; Dieter Leibfritz; Charles L Edelstein; Joshua M Thurman; Uwe Christians
Journal:  J Proteome Res       Date:  2012-10-11       Impact factor: 4.466

2.  Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.

Authors:  Jelena Klawitter; Douglas J Kominsky; Jaimi L Brown; Jost Klawitter; Uwe Christians; Dieter Leibfritz; Junia V Melo; S Gail Eckhardt; Natalie J Serkova
Journal:  Br J Pharmacol       Date:  2009-08-06       Impact factor: 8.739

3.  Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.

Authors:  Lori A Gardner; Jelena Klawitter; Mark A Gregory; Vadym Zaberezhnyy; Dmitry Baturin; Daniel A Pollyea; Naoko Takebe; Uwe Christians; Lia Gore; James DeGregori; Christopher C Porter
Journal:  Am J Hematol       Date:  2014-06-19       Impact factor: 10.047

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.